Business Description
Ligand Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US53220K5048
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 50.14 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.04 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 10.41 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.7 | |||||
3-Year EBITDA Growth Rate | 18.7 | |||||
3-Year EPS without NRI Growth Rate | 22.2 | |||||
3-Year Book Growth Rate | -3.3 | |||||
Future 3-5Y EPS without NRI Growth Rate | 107.12 | |||||
Future 3-5Y Total Revenue Growth Rate | 17.49 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.76 | |||||
9-Day RSI | 45.88 | |||||
14-Day RSI | 48.27 | |||||
6-1 Month Momentum % | 16.41 | |||||
12-1 Month Momentum % | 13.74 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 20.7 | |||||
Quick Ratio | 19.51 | |||||
Cash Ratio | 17.43 | |||||
Days Inventory | 841.99 | |||||
Days Sales Outstanding | 95.35 | |||||
Days Payable | 169.82 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | 6.67 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 91.82 | |||||
Operating Margin % | -1.18 | |||||
Net Margin % | 81.43 | |||||
FCF Margin % | -16.27 | |||||
ROE % | 13.82 | |||||
ROA % | 11.93 | |||||
ROIC % | -0.19 | |||||
ROC (Joel Greenblatt) % | 192.94 | |||||
ROCE % | 15.82 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 15.86 | |||||
Forward PE Ratio | 24.75 | |||||
PE Ratio without NRI | 21.4 | |||||
Shiller PE Ratio | 12.5 | |||||
Price-to-Owner-Earnings | 15.66 | |||||
PS Ratio | 12.64 | |||||
PB Ratio | 1.88 | |||||
Price-to-Tangible-Book | 3.69 | |||||
Price-to-Operating-Cash-Flow | 43.83 | |||||
EV-to-EBIT | 9.92 | |||||
EV-to-Forward-EBIT | 18.87 | |||||
EV-to-EBITDA | 7.71 | |||||
EV-to-Forward-EBITDA | 18.87 | |||||
EV-to-Revenue | 10.24 | |||||
EV-to-Forward-Revenue | 8.57 | |||||
EV-to-FCF | -61.73 | |||||
Price-to-Projected-FCF | 1.19 | |||||
Price-to-Median-PS-Value | 1.24 | |||||
Price-to-Graham-Number | 1.87 | |||||
Price-to-Net-Current-Asset-Value | 5.78 | |||||
Price-to-Net-Cash | 7.44 | |||||
Earnings Yield (Greenblatt) % | 10.08 | |||||
FCF Yield % | -1.29 | |||||
Forward Rate of Return (Yacktman) % | -9.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ligand Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 109.402 | ||
EPS (TTM) (€) | 4.882 | ||
Beta | 1 | ||
Volatility % | 45.58 | ||
14-Day RSI | 48.27 | ||
14-Day ATR (€) | 1.549635 | ||
20-Day SMA (€) | 75.05 | ||
12-1 Month Momentum % | 13.74 | ||
52-Week Range (€) | 46.4 - 81 | ||
Shares Outstanding (Mil) | 17.96 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ligand Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ligand Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ligand Pharmaceuticals Inc Frequently Asked Questions
What is Ligand Pharmaceuticals Inc(STU:LGDN)'s stock price today?
When is next earnings date of Ligand Pharmaceuticals Inc(STU:LGDN)?
Does Ligand Pharmaceuticals Inc(STU:LGDN) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |